Science biotechnology has been attributed a superior platform in Malaysian government plan for wealth creation in the 9th Malaysian plan and policy of Malaysia's science and technology in 21st century; it has been accepted and categorized as a complicated emerging issue to illustrate high prominence combined with restricted knowledge in environment. Researchers emphasize on the importance of biotechnology knowledge evaluation to shape people's attitudes about technologies after acquirement of related information. Biotechnology industry has been developing dramatically all around the world since 30 years ago and it attempts to evolve technological and scientific information. Especially, developing countries struggling to fight against hunger via agricultural applications showed interest with this regard. Research on accelerating the rate of biotechnology innovation acceptance is necessary and useful to help the policy makers, researchers and biotechnology companies to ensure their effectiveness and growth.
INTRODUCTION
Today the perspective of biotechnology as a significant science has proposed considerable potential development for environmental compatibility, economic viability and social responsibility. Biotechnology is the next wave of knowledge-based activities to contribute and create wealth, new investment, challenges and opportunities of employment as well as environmental, social and economical vantages. It is recognized as an important key technology to drive and support knowledge-based opportunities (Amin and Ibrahim, 2011) . Developing countries fail to keep up with the established pace in the new bio-economy according to institutional insufficiency (Buctuanon, 2001 ). There are three sectors and areas in biotechnology science, the first one Industrial biotechnology (also referred to as "White Biotechnology"), second one is Healthcare biotechnology ("Red biotechnology") and the last one is Agricultural biotechnology ("Green biotechnology"). The Malaysian Biotechnology Information Center (MABIC) attempts to make technical information accessible to non-technical individuals, enhance public biotechnology awareness level and support the government's effort to develop biotechnology as an effective power to enable economic growth (9th Malaysian Plan, 2006) . The goal of public and private sectors is to facilitate and acquire biotechnology applications obtained from industrial countries to developing ones for more benefits; and also the mission of the government is alleviating poverty by enhancing productivity, generating more income and providing a safe environment for more sustainable development. A comprehensive framework is provided by National Biotechnology Policy in 2005 to conduct biotechnology development efforts and outline goals, strategies and priorities. It is predictable that the support will be performed by strong existing of natural resources and human capital talent by government.
Biotechnology in Malaysia is the prime mover to act and catalyst the knowledge from related articles and publications like: Overview-Malaysian industrial biotechnology (2009) , that discussed about rapid growth . Obviously, government is an important hub to strive to grow the Malaysian biotechnology program and accelerate biotechnology innovation to create more benefits; it attempts to achieve milestone as soon as possible in future by past accomplishments. So the goal of innovation policy is facilitate and develop the application of biotechnology in Malaysia and promote scientific advances of public understanding; it also creates more productivity, more capability for government and economic sectors. Based on mentioned details the main goal of this paper is to accelerate the speed of biotechnology innovation in phase two (2010 to 2015), convergence tendency and estimation efficiency of Ministry of Science Technology and Innovation (MOSTI) programs.
MATERIALS AND METHODS
To accelerate biotechnology innovation the MOSTI programs was efficient and it was the first goal of this study. It can be mentioned in some active academic centers in Malaysia in field of agriculture biotechnology, Universiti Putra Malaysia (UPM), Universiti Malaya (UM), Universiti Kebangsaan Malaysia (UKM), Universiti Sains Malaysia (USM). In bio-valley project, these universities are the principal participants. USM is an exception in this field of study because its concentration is on pharmaceuticals biotechnology not on agricultural biotechnology. The number of biotechnology researchers who are working in UM, UKM, UPM based on information of official website of universities is 98 (Farid et al., 2010) .
MOSTI in Malaysia declared the number of agriculture biotechnology companies which are supported by this organization was 51 . Investigation of whole target population sample faces to some restrictions and according to mentioned criteria target populations are viewed to be the same in this survey based on belief of Creswell (2008) and Thompson (2002) .
To do the data collection, a questionnaire has been designed and this research was performed quantitatively. The questionnaire is made by the researcher and a pilot test and board of specialists guaranteed its validity. Cronbach's alpha internal consistency assisted to measure the reliability of the questionnaire (Levy and Lemeshow, 2008; Cohen et al., 2007; Ary et al., 2006) . The questionnaire has been replied by 24 academic staff from USM university of Biological Science department and 10 Malaysian biotechnology companies to manage and conduct the pilot test reliability. The only non-participants of target population research were stated respondents and the reason is area of their biotechnological activities which is concentrated on pharmacological not on agricultural; but to measure the validity of the questionnaire they are picked up because of the same field of their work. Biotechnology and academic members have prepared two adapted versions of questionnaires. Cronbach's alpha was utilized for any single item of the questionnaire. Academic members who are experts in field of biotechnology in universities and companies, R&D managers and director management, replied to distributed questionnaire and 0.880 and 0.902 is the result of reliability coefficient (Table 1 ). It is indicated that all coefficients were more than 0.70 and stability and consistency in distinctive constructs of items can be seen in corresponding answers. 51 companies in field of agricultural biotechnology and 98 academic members and experts who are working in biotechnology filed in UPM, UM, and UKM universities received the validated and reliable questionnaire. Rate of feedback for participants in university was 89.79% (N = 88) and rate of biotechnology company managers response was 90.19% (N = 46) .
To carry out Logit model this data was used. Data collection by the questionnaire encompasses nominal, ordinal, and ratio scales. Nominal form refers to some questions about some aspects of personal characteristics like, activities companies and publication channel, experience and gender. In likert-type data collection, questions are in the form of ordinal and questions about age, experience and financial position are in the form of ratio. This data can be seen in distinctive statistical analysis. Descriptive statistics defined data rudimentary features and statistic summary. Male and female were the respondents in universities, 38.6% males and 61.4% female with the age of 35 to 58 years old. The responses were listed as follow: 35 to 40 years were 25%, 41 to 45 years were 29.5%, 46 to 50 years were 27.2%, 51 to 55 years were 14.7%, and more than 55 years old were 3.4%. Age factor mean is 45 years. It should be considered that education level of all the academic staff members were Ph.D. degree (N = 88). 43.2% professor, 28.4% associate professors, 23.9% senior lecturers and 4.5% lecturers were respondents in the analysis. All respondents who were 88 answered the questionnaire. 5 to 21 years were the range of academic experience. Classification of responses is defined as follow: for the range of 5 to 10 years' experience were 42%, 11 to 15 years were 29.5%, 16 to 20 years 27.2% and more than 21 years' experience were 1.1%. Academic experience mean was 12 Annually no more than two innovation adoptions can be received by academic researchers based on data representation; it is fixed in an agreement which includes less than two innovations rating with low measurement. 28.3% females and 71.7% males involved in biotechnology companies were compared and 46 responded questionnaires were collected. Respondents' age range was 31 to 58 years old. 30 to 35 years = 19.6%, 36 to 40 years = 26.1%, 41 to 45 years = 23.9%, 46 to 50 years = 21.7%, 51 to 55 years = 2.2% and more than 55 years = 6.5%. 42 was age factor mean. The percentage of R&D managers was 63.0% and director management's participation was 37.0%. The education degree and level of participants this group and company were bachelor's degree (N = 4.3%), master degree 65.2% and Ph.D. holders were 30.4%. Range of participants' experiences was from 3 to 16 years; where, 1 to 5 years = 21.7%, 6 to 10 years = 58.7%, 11 to 15 years = 17.4%, and more than 15 years = 2.2%. Mean for the factor of working experience length was 8 years.
Possibility of an event happening between independent variables which include knowledge, acceptance, funds, cooperation and technology transformation and dependent variables, biotechnology innovations adoption rate was measured by Logistic regression (Logit model).
Logistic regression
The present research analyses a problem with five independent variables and 1 dependent variable which is biotechnology innovations adoption rate. To have exact and precise estimation a new method for measuring the adoption rate in social science was found, the logistic regression (Adeogun et al., 2008) . While the target variables are classified into two categories to form a categorical variable, logistic regression was utilized as a predictive model. A decision tree is included in logistic regression model that relates to nonlinear regression like a set of data values as fitting a polynomial. Logistic regression has significant role since it has several advantages in distinguish analysis. Actually, independent variable and dependent variables are not normally distributed and it seems there is no relationship between dependent and independent variable. Also nonlinear effect may be managed. It should be mentioned that there is no homogeneity in variance supposition.
Hosmer and Lemeshow (2000) have spoken about the advantage of logistic regression model to linear regression model, demonstrating the connection and relationship between the dichotomous attributes of interest and set of independent variables to discover the best fitting model is the aim of logistic regression. To predict the possibility of interest presence in logit transformation, logistic regression creates the coefficients (and its standard errors and significance levels) of a formula:
Where, is the possibility of the characteristic of interest presence and specified by the logistic function:
The definition of logit transformation as the log odds indicates as:
and therefore the logits ( natural log of the odds), of the unknown binomial possibilities are designed as a linear function of the generally known as link function as:
The logit model supposed that underlying stimulus index is a random variable, which anticipated the possibilities of biotechnology innovation adoption:
To calculate and analyse the possible effectively of MOSTI programmes on speeding up the rate of biotechnology innovations, the preceding formula have been applied and the probabilities and chances of adopting the innovations is predictable.
RESULTS
Calculations and information about the number of biotechnology innovations created by academics which have been displayed to public is shown in public (including biotechnology companies) for researchers was low. In agreement of used scale, the median of value rate was 0.75 and standard deviation was 0.19. Rate of mean was 0.66. Rating of less than two innovations is considered as low; based on this rating level Table 2 displays that no academic researchers had more than two innovation adoption annually.
There is a summary of information about number of personnel who trained in field of biotechnology and had cooperation with each company in Table 3 that illustrated briefly by Farid (2011) . This table represents the percentage of companies and number of trained personnel; Concentration of this research is on biotechnology innovations of agricultural and target population includes only companies which are active in this field. The total number of involved companies is 46; the percentage of non-GM agricultural biotechnology companies was 19.6% while only 10.9% of companies were cooperating in the industrial processing field. The technological innovation connection activities performed by the participant companies encompass financing, dissemination, development, introduction/ selling, evaluation, training, use and purchase which are shown in Table 3 . The percentages for any single type of activity were 15. 2, 21.7, 8.7, 10.9, 19.6, 8.7, 10.9 , and 4.3%, respectively.
Information and calculation are shown in Tables 4 and Table 4 . In agreement with low adopted innovation which is considered as less than two, seven companies were high in innovation adoption while 39 companies were low in this process. 1.50 was the median value rate, standard deviation was 0.75. The results of data collection analysis which has been done by logistic regression are presented in Table 6 ; collected data refers to 46 biotechnology companies and 88 questionnaires returned from university biotechnology academics. Explanation about the details of analysis is indicated below the table.
In Table 6 in the case procedure, no absence of values can be seen and all 88 questionnaires returned and replied by university biotechnology academics; they are utilized via logistic model analysis. 46 questionnaires which have been answered by biotechnology companies are included in analysis. Therefore in Table 6 , throughout case procedure no missing value is seen. It is considered to utilize performed conversion of variables value to binary values and attempt to fit them in logit model. Five values are designed according to Likert scale (strongly disagree, disagree, somewhat agree, agree, strongly agree). Positive values (somewhat agree, agree and strongly agree) were equal to the value 1 while the nega- 
Biotechnology companies
Step 1 "Exp (B)" is appointed in exponentiation of the coefficients and explained and clarified them as oddsratios. It is the anticipated change in odds for any single unit goes up in the independent variable correspondent. It is considered that odds ratios which are less than 1.0 correspond will be reduced and odds ratios more than 1.0 correspond will increase in odds. Odds ratios near to 1.0 exhibit that changes of unit in that independent variable do not impact and affect the dependent variable. If pvalue of independent variables, level of cooperation (Avr.E), amount of fund (Avr. C), level of transfer of technology (Avr.F), level of knowledge (Avr.B) and level of acceptance (Avr. D) is 0.05 or lesser; the null hypothesis, no difference between the coefficients (B) of independent variables can be refused. Table 7 illustrates that the p-value of independent variables (Avr. C and Avr.F) are less than 0.05, therefore the null hypothesis, that there is no difference between the coefficients (B) of independent variables, is rejected for academic researchers. Also first part of Table 7 that shows academic researchers' data demonstrates that Avr.C (amount of fund) and Avr.F (level of transfer of technology) are statistically significant with p-values of 0.029 and 0.002, respectively while, Avr.B (level of knowledge), Avr.D (level of acceptance) and Avr.E (level of cooperation) are not. Exp (B) (odds ratio) is used for logical interpretation. It can be said that for a one unit change in Avr.C and Avr.F, the Exp(B) of effect of MOSTI programs on accelerating biotechnology innovation changes by a factor of 14.678 and 45.253, respectively for academic researchers. The estimated model is used to predict probability of effect of MOSTI programs on accelerating biotechnology innovation from academic researchers' viewpoint:
In this study, 5 units are considered for predictors, then the level of possibility of adoption and acceptance of biotechnology companies are calculated as follows:
= −28.620 + 2.686 + 3.812 = −28.620 + 2.686 × 5 + 3.812 × 5 = 3.87
Percentage of chance based on MOSTI program support dedication to biotechnology innovation to speed up this process from point of view of university academics is 97%; while all remaining factors are constant and stable and just 5 units are dedicated to predictors. The second part of Table 7 belong to biotechnology companies' data that illustrates the p-value of independent variables (Avr.F) is less than 0.05, therefore the null hypothesis, that there is no difference between the coefficients (B) of independent variables, is rejected for biotechnology companies. In addition, this table shows that Avr.F (level of transfer of technology) is statistically significant with p-values of 0.038, while Avr.B (level of knowledge), Avr.C (amount of fund), Avr.D (level of acceptance) and Avr.E (level of cooperation) are not. Exp (B) (odds ratio) is used for logical interpretation. It can be said that for a one unit increase in Avr.F, the exp (B) of effect of MOSTI programs on accelerating biotechnology innovation increases by a factor of 1.733E4 for biotechnology companies.
Probability of the effects of MOSTI programs on accelerating biotechnology innovation is calculated by the following formula for biotechnology companies: 
According to MOSTI program 99% chance for company to adopt and accept biotechnology innovation is possible based on obtained results, when all other thing is constant and stable. More detail can be found in Table 9 . Totally dependent variable is impacted by every single independent variable; in above calculation average of response for dependent variable is the reason for this influence. Understanding and comparing of outcomes is easy by 
DISCUSSION
Adoption rate is computed and measurement of possibility of biotechnology innovation according to main factors of logistic regression is conducted. It is explained in the following discussion about university and companyrelated data. Predicting innovation adoption possibility by companies is one of the major advantages of logistic regression. Economic justification and strategies of empirical model in Malaysia has been drawn and improved by biotechnology innovation based on agreement of universities researchers. Each unit possibility is anticipated by logistic regression model and it has been done for predictors. Graph of adoption possibility is designed when every single unit is assigned to predictors and change of percentage representation in biotechnology adoption chances by mentioned companies is so clear through this graph. All graph codes are run with MATLAB 7.0 software and all algorithms are done on a PC with Core DUA CPU. Table 9 and Graphs 1 and 2 exhibit chances for different allocated units. The possibility of biotechnology innovations acceptance is represented obviously in the graph. In Figures 1 and 2 , unit values for predictors is indicated by X axis and Y axis possibility in effect of MOSTI programs on accelerating biotechnology innovation adoption is shown while other factors are stable.
As can be seen in Figure 1 , the acceptance possibility of effect of MOSTI programs on accelerating biotechnology innovation will occur by companies and it is 100% if allocated units are a bit more than 5 for predictors. The following graph exhibits chance of effect of MOSTI programs on accelerating biotechnology innovation for each unit value which is allocated to predictors. It is interpreted that adoption chance is not raised up in a monotonous way. To have the chance more than 0%, around 4 allocated units should exist for predictors. It means that when the selected number for units is between (0, 4), adoption chance Is still 0% as view of academic researchers. The slope, interval [4, 6) is the most important and effective interval to speed up the chance of adoption, as it rises up very fast from near 0 to 100%. As represented, in Figure 2 the possibility of acceptance by companies is 100% if the allocated units for predictor are 5 and the possibility of acceptance can be 0% if allocated units are less than 3. It means that the consequence of one unit in interval (3.5, 4.5) is most impressive and effective, and can rise up adoption chance from 0 to 100%.
Conclusion
Based on university researches, economic growth and benefits in Malaysia can be achieved by biotechnology innovation and it is a powerful tool which represents environmental, economical and social vantages. Creation of new products, new innovation and new companies are big issues in Malaysia. Based on assessment and data collection analysis need for biotechnology can be sensed and wide efforts are being performed by Malaysian government to have comprehensive and measured framework.
Technological innovation in competitive world has great role in science, research and investment of technology; investment at the beginning of research stage leads to find its potential. To utilize and control these opportunities it is important to find effective, leveraged and scalable way to bridge them from MOSTI programs to research centers of universities.
The results of this study show that only the factor of level of transfer of technology is known as a common effective factor both for academic researchers and biotechnology companies. This shows that these very important sectors do not have sufficient understanding about each other's needs and therefore are not able to collaborate effectively. The government should pay more attention to provide researchers with sufficient information about the companies' needs and demands and on the other hand, companies should be informed about the innovations made by university researchers. This collaborative work among government, researchers and companies are inevitable if policy makers are interested in accelerating the rate of biotechnology innovation adoption and use biotechnology as an engine of growth in economical and scientific aspects.
Innovative process depends on sufficient fund and budget and also technology transformation level from the perspective of researchers. More concentration on these aspects is needed to accelerate biotechnology innovation as one of the important goals to form a technology transformation by MOSTI. By allocating sufficient funds and restricting providing the funds to those companies and researchers who are more interested in collaborating, MOSTI may be able to achieve its goals with regard to accelerating the rate of biotechnology innovation creation and adoption in biotechnology companies and academic research centers.
